An antibody-drug conjugate ... with another $1.525 billion in success-based milestones. It is playing catch-up with another B7-H3 ADC candidate from MSD and Daiichi Sankyo, ifinatamab deruxtecan ...

The partnership unites RAD's products with AtomVie's capabilities in the manufacture and distribution of radiopharmaceuticals.

Pain significantly affects the quality of life and antibodies are being explored as a novel pain-relieving strategy.

Tecentriq is a monoclonal antibody designed to bind with a protein ... blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, Tecentriq may enable the re-activation ...

The companies will collaborate to hold a global Phase I combination trial of YL201 and Amgen’s Imdelltra for small cell lung ...

The company highlighted in its statement the recent start of the IDeate-Lung02 of B7-H3-directed antibody-drug conjugate ... Therapeutics which is in phase 1/2.

ASX-listed Radiopharm Theranostics has joined forces with a renowned global radiopharmaceutical manufacturer to produce its cancer-fighting treatment that targets commonly over-expressed protein in ...

Only 3 (1%) were reported as treatment related interstitial ... LINker-payload (TMALIN®) conjugated with a highly specific B7-H3 antibody. Currently, YL201 is being investigated in four Phase ...

Top-line, phase 3 results for Bristol-Myers Squibb's humanized monoclonal antibody ... cell receptor B7, together with antigen presentation to the T-cell receptor (Fig. 1). Such 'co-stimulation ...

"Inebilizumab is a humanized monoclonal antibody that causes targeted and sustained depletion of CD19-positive B cells, ...

ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, today announced that it has entered into a ...

Co., Ltd. ("MediLink"), a clinical-stage biotech company, today announced a global clinical trial collaboration and supply ...